Atn-50

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atn-50

What is Atn-50?

Atn-50 is an investigational therapeutic agent developed for the management of specific chronic conditions. It belongs to a class of compounds designed to interact with targeted biological pathways to modulate the body's physiological response. Unlike conventional treatments, Atn-50 focuses on cellular signaling mechanisms to address the underlying biological activity associated with certain diseases.

Mechanism of Action

The primary function of Atn-50 involves the selective binding to specific receptors on the surface of target cells. By engaging these receptors, the compound can either inhibit or enhance certain intracellular processes. This targeted approach aims to restore balance within biological systems that have been disrupted by illness. Research into Atn-50 explores how this molecular interaction may lead to a reduction in symptoms or a change in the progression of the condition being studied.

Composition and Development

Atn-50 is a synthetic molecule engineered for high stability and precision. Its development involves advanced biochemical modeling to ensure that the compound interacts specifically with its intended targets while minimizing interactions with unrelated systems in the body. The development process prioritizes a clear understanding of the drug’s pharmacokinetic properties—how the body absorbs, distributes, and processes the substance.

Therapeutic Context

In a clinical context, Atn-50 is being evaluated for its potential role in long-term treatment strategies. It is typically considered in cases where existing therapeutic options may not be sufficient or where a different biological approach is required. The focus of its application is to provide a specialized option for patients, contributing to a more comprehensive range of available therapies for complex health needs.

What side effects are possible with Atn-50?

Possible side effects and safety information

Atn-50 (Atenolol) is associated with an official safety profile categorized by the frequency and body system affected, as documented in regulatory sources such as the FDA and EMA. Understanding this profile involves recognizing the most common and the most serious documented adverse reactions.

Commonly Documented Adverse Reactions

Side effects classified as common (occurring in 1/100 to 1/10 patients) include bradycardia (slow heart rate), fatigue, and cold extremities, alongside general gastrointestinal disturbances. Effects classified as uncommon include sleep disturbances and elevated liver transaminases. Rare events may involve psychiatric disorders (e.g., mood changes, nightmares), CNS effects (e.g., dizziness, headache), visual issues, and dermatological reactions.


Serious Adverse Reactions and Safety Constraints

Serious adverse reactions documented in regulatory documents pertain mainly to the cardiovascular system, including the exacerbation of pre-existing heart failure and the precipitation of heart block. For patients with underlying bronchial disease, bronchospasm is a serious safety concern. The use of Atn-50 is contraindicated in specific severe conditions such as severe sinus bradycardia, uncontrolled heart failure, and cardiogenic shock.


Population and Exposure-Related Safety Notes

The label includes specific safety considerations for certain patient groups. Individuals with diabetes may not experience the usual warning signs of low blood sugar (hypoglycemia). Renal impairment necessitates a dose adjustment due to the drug's excretion route. A critical safety pattern noted is the risk of severe cardiovascular events, such as myocardial infarction or worsening angina, following the abrupt cessation of treatment. Therefore, therapy must not be stopped suddenly.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Atn-50

Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations Clinical manifestations include lethargy, severe bradycardia (slow heart rate), hypotension (low blood pressure), wheezing, and hypoglycemia.
Physiological systems affected (as stated in label) Adverse effects involve the cardiovascular system (e.g., congestive heart failure, cardiogenic shock), the respiratory system (bronchospasm), and the central nervous system (e.g., coma, seizures).
Dose-related or exposure-related factors (if applicable) Risk is associated with the ingestion of doses higher than those prescribed.
Population-specific overdose notes (if applicable) Neonates of treated mothers are documented to have an increased risk of hypoglycemia and bradycardia following exposure.
Emergency-response statements (as written in official documents) Treatment must be directed to the removal of unabsorbed drug using described procedures like gastric lavage or activated charcoal administration.
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention for all suspected overdose cases. Local emergency services must be contacted if symptoms are perceived as life-threatening.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification (as defined in official documents) Overdose may be associated with life-threatening outcomes, requiring hospital monitoring.
Regulatory basis (EMA / FDA / etc.) The information is derived from official government regulatory documents, including FDA Prescribing Information and EMA Summary of Product Characteristics (SmPC).
Overdose-context constraints (as defined in official documents) The medication is documented to be removable from the general circulation by hemodialysis.

Resulting Overdose Structure

Official overdose statements:

  • Overdose presents with signs of systemic depression, including severe bradycardia and hypotension.
  • Severe, life-threatening outcomes such as cardiogenic shock, coma, and seizures are documented.
  • Immediate medical attention is required for suspected overdose, with initial treatment focused on removal of unabsorbed drug and symptomatic supportive care.
  • No specific antidote is explicitly designated in the official regulatory documents.

Connection to the Overall Overdose Profile

The regulatory documents define the overdose profile by strictly listing specific symptom clusters and severe outcomes related to cardiovascular and CNS depression. This information directly mandates seeking immediate medical help and directs medical professionals toward specific supportive and removal procedures (e.g., hemodialysis, gastric lavage), thereby establishing the necessary emergency response conditions as required by government health authorities.

Therapeutic Uses of Atn-50

Quick Facts: Atn-50 (Atenolol) Therapeutic Overview

  • Support for managing high blood pressure (hypertension).
  • Assists in the long-term management of chest discomfort (angina pectoris).
  • Contributes to care for individuals after a heart attack (acute myocardial infarction).

What Atn-50 treats: main uses and benefits

Atn-50 (Atenolol) is a prescription treatment that is frequently utilized to support the management of key cardiovascular conditions. It is primarily administered to assist in maintaining blood pressure levels within a specified range for individuals diagnosed with hypertension.

In the setting of heart disease, Atn-50 is also an established option for the long-term care of chest discomfort associated with coronary artery conditions, known as angina pectoris. The medication may be a component of the management protocol to support the reduction of complications in hemodynamically stable patients following an acute myocardial infarction (heart attack).

Additionally, healthcare professionals may utilize this therapy to support the maintenance of regular heart rhythm in some individuals experiencing certain cardiac rhythm changes (arrhythmias).

Use of this medication should always be aligned with the judgment and direction of a qualified healthcare provider.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Atn-50?

This section describes the official population eligibility rules for Atn-50 (Atenolol), based strictly on governmental regulatory documents. Eligibility is defined by specific conditions, organ function, and age group.


Populations for Whom Use is Contraindicated

Atn-50 is contraindicated and must not be used by individuals with severe pre-existing conditions, including cardiogenic shock, uncontrolled heart failure, Sinus Bradycardia (heart rate leq 50 beats per minute), 2^nd or 3^rd Degree Heart Block, Sick Sinus Syndrome, Severe Asthma, Severe COPD, Metabolic Acidosis, or Untreated Phaeochromocytoma.

Eligibility Rules and Restrictions

Category Official Regulatory Status
Established Population Adults are the established population for use.
Pediatric Use Not established or not recommended due to insufficient data on safety and efficacy.
Renal Impairment Restricted use is necessary; dose adjustment is mandatory for patients with significant renal impairment (e.g., creatinine clearance < 35 mL/min).
Pregnancy/Lactation Restricted or not recommended due to risks of fetal harm, such as intra-uterine growth retardation, and significant drug accumulation in breast milk.

Use requires caution in patients with Controlled Heart Failure, First-Degree Heart Block, and Diabetes Mellitus.

What should I know about interactions with other medicines?

Atn-50 Interactions with other medicines and products

The official regulatory profile for Atn-50 (atenolol) is primarily structured around pharmacodynamic interactions that affect heart function and blood sugar regulation. Due to minimal hepatic metabolism, interactions are largely related to additive physiological effects, absorption interference, and renal clearance.

Interactions Affecting Heart Function

Co-administration with other medicines that reduce heart rate or blood pressure may result in documented additive effects. For instance, combining Atn-50 with calcium channel blockers of the Verapamil or Diltiazem-type, or with certain antiarrhythmics like Amiodarone, carries the documented risk of severe cardiovascular depression, including marked hypotension or bradycardia. The antihypertensive effect of Atn-50 may be antagonized and reduced by the concurrent use of Prostaglandin Synthase Inhibitors, such as non-steroidal anti-inflammatory drugs (NSAIDs).

Procedural and Pharmacokinetic Constraints

Antacids containing Aluminum Hydroxide reduce the absorption of Atn-50, requiring that the administration of these products be separated by two hours. For patients also taking Clonidine, regulatory guidelines stipulate that Clonidine withdrawal must be delayed until several days after the cessation of Atn-50 to mitigate the documented risk of rebound hypertension. Furthermore, Atn-50 can mask the clinical signs of hypoglycemia (such as tachycardia) when co-administered with Insulin or Oral Antidiabetics. In patients with renal impairment, clearance is significantly reduced, prolonging the drug’s half-life.

Mechanism of Action

Atn-50's action is governed by its role as a selective competitive antagonist primarily targeting the mathbfbeta1 -adrenergic receptor. This engagement is central to two key mechanisms that establish the drug's physiological profile.


Dampening beta1 Receptor-Mediated Cardiac Activity

This domain covers the molecular interaction where the active ingredient blocks the cardiac beta1 receptors from binding to stimulating neurotransmitters like norepinephrine and epinephrine. This interruption of the sympathetic nervous system signal cascade directly results in the crucial physiological effects of negative chronotropy (slower heart rate) and negative inotropy (reduced force of contraction). This combined action decreases myocardial oxygen demand and reduces cardiac output.


Modulating Hormonal Regulation via the Kidneys

The mechanism also extends to the kidneys, where beta1 receptor blockade suppresses the release of the enzyme renin from the juxtaglomerular cells. Since renin initiates the powerful Renin-Angiotensin-Aldosterone System (RAAS), this action modulates a major humoral pathway that controls blood vessel tension. This modulation influences systemic vascular resistance and alters cardiovascular dynamics.


️ Understanding Mechanism Limits: Dose-Dependent Selectivity

The primary mechanism relies on the agent's preference for beta1 receptors, but this selectivity is dose-dependent. At concentrations higher than typically required, the drug can begin to block the mathbfbeta2 -adrenergic receptors found in smooth muscle, which represents a functional constraint on the primary mechanism. This loss of specificity can lead to the physiological consequence of bronchoconstriction in tissues where beta2 receptors are dominant.

Dosage and Administration Information

Atn-50, which contains the active ingredient atenolol, is administered with specific consideration for the appropriate route, frequency, and dose adjustments. The primary use pattern relies on the oral administration of tablets for chronic maintenance, while the intravenous (IV) injectable solution is reserved for immediate intervention in acute clinical settings.


Standard Dosing and Frequency

For chronic management, such as hypertension, the standard oral therapy is initiated at 50 mg once daily. If the clinical response is insufficient after approximately one to two weeks, the dose may be increased to a maintenance level, typically 100 mg once daily. Doses for angina pectoris may range higher, with some regimens allowing up to 200 mg daily. The tablets are intended to be swallowed whole with water and may be taken with or without food.


Procedural and Population Requirements

A critical procedural requirement is the adjustment of dosage for patients with impaired renal function. Maximum daily dose restrictions are utilized based on the patient’s creatinine clearance to prevent drug accumulation. Furthermore, a lower starting dose, such as 25 mg once daily, is often advised when initiating therapy in older adults. A key restriction is the required protocol for discontinuation: therapy must never be stopped abruptly but instead requires a gradual dose reduction (tapering) over a period of one to two weeks. This structured use pattern defines the administration of the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Atn-50 (Atenolol)


Evidence for use in Essential Hypertension (High Blood Pressure)

Clinical research for Atn-50 was evaluated in multiple study types, including Randomized Controlled Trials (RCTs) and meta-analyses. These studies were used in research exploring how outcomes related to functional imbalance change over time in adults with high blood pressure, comparing Atn-50 against placebo or other established antihypertensive drug classes. Studies consistently reported measurements indicating differences in both systolic and diastolic blood pressure between the study groups. However, the long-term findings related to cardiovascular outcomes were observed in trials that often compared Atn-50 against other existing drug classes at the time of the study.

Evidence for use in Chronic Stable Angina Pectoris (Chest Pain)

Atn-50 was evaluated in clinical trials exploring outcomes related to episodic or acute changes in patients with chronic stable angina. Research examined the number of chest pain episodes reported by patients and the frequency with which they needed to use other short-acting nitrates. Studies monitored how symptoms evolved in the observed populations, and findings describe patterns associated with differences in the frequency of anginal attacks. Research also utilized exercise tolerance testing and monitored metrics related to the duration patients could exercise before experiencing symptoms became more noticeable.

Evidence for use after Acute Myocardial Infarction (Heart Attack)

Large-scale randomized trials studied the use of Atn-50 after a heart attack. Studies conducted in the acute setting observed patterns showing an association between the early administration of Atn-50 and measurements related to vascular mortality during the acute phase. The strongest evidence stems from trials conducted in the pre-reperfusion era, meaning the direct applicability of these findings to current treatment involving current standard revascularization or treatment methods may require further consideration.

What Remains Uncertain in the Research Evidence

Comparative evidence is lacking for a direct assessment against drug classes developed more recently regarding major long-term event reduction in hypertension. Subgroup findings remain limited or uncertain, as data for certain groups, such as children or pregnant individuals, remain insufficient. Overall, existing studies provide limited insight into how the evidence for Atn-50 compares to every alternative treatment currently available across all of its indications.

Key Studies & References

  1. NIH MedlinePlus Drug Information: Atenolol (Oral Route)
  2. National Institute for Health and Care Excellence (NICE) Guideline: Chronic heart failure in adults: diagnosis and management (Evidence for beta-blocker use)

Frequently Asked Questions (FAQ)

Common questions about Atn-50 (FAQ)


Q: Is Atn-50 a drug that needs to be taken daily?

Official guidelines describe the standard oral therapy for the chronic management of conditions like high blood pressure (hypertension) as being initiated once daily. This frequency is established in the product information for ongoing use.


Q: Can Atn-50 cause changes in mood?

Yes, official safety documents list mood changes and depression as adverse reactions that have been reported with Atn-50. These types of psychological effects are typically classified in regulatory materials as rare or less common occurrences.


Q: Is it normal to feel a change in appetite when starting Atn-50?

Official safety documents commonly classify gastrointestinal disturbances (issues related to the stomach or intestines) as a potential side effect. While loss of appetite has been reported in some adverse event databases, it is less commonly listed than general digestive issues.


Q: Are there any common foods or drinks that should be avoided while using Atn-50?

According to the official product information, there is a requirement to separate the administration of Atn-50 from antacids containing Aluminum Hydroxide by at least two hours. This is because these types of antacids can interfere with how the drug is absorbed by the body.


Q: What research studies support the use of Atn-50?

The drug's regulatory approvals are supported by clinical evidence, including Randomized Controlled Trials (RCTs). These studies examine its use in approved areas such as high blood pressure, chest pain (angina), and treatment following a heart attack.


Q: What if Atn-50 does not seem to be working for me after a few weeks?

Official regulatory guidelines state that if the clinical response to the starting dose is insufficient after approximately one to two weeks, a dose adjustment may be explored by a healthcare provider to achieve the expected clinical response.


Q: How long does it typically take for Atn-50 to start working?

The drug's core action, which involves blocking beta receptors, is measurable within one hour after a single oral dose. However, the full impact of the drug on managing conditions like high blood pressure is often assessed over a period of one to two weeks.


Q: Can Atn-50 make me feel dizzy or tired?

Yes, the official safety profile lists fatigue and tiredness as commonly reported adverse reactions. Dizziness is also listed as an adverse reaction that can occur when taking this medication.


Q: Is the onset of Atn-50 immediate or does it build up over time?

The direct beta-blocking effects of the drug begin relatively quickly, becoming apparent within 1 hour of taking it. For chronic conditions, the full benefits, such as a sustained reduction in blood pressure, are maintained with continued daily use.


Q: Is Atn-50 a type of antibiotic?

No, Atn-50 is officially categorized as a beta-blocker. This type of medicine works by blocking certain receptors in the body, primarily to affect the heart and blood vessels, and is not used to treat bacterial infections.


Q: How is Atn-50 different from other similar treatments?

Official documents describe Atn-50 as a selective competitive antagonist primarily targeting the beta1 ext-adrenergic receptor. This technical description highlights its preference for blocking a specific type of beta receptor, which is one way it is distinguished from other drug classes.


Q: Does Atn-50 cause weight gain or loss?

Official safety data has documented weight gain as a reported side effect of the drug class to which Atn-50 belongs, particularly in the context of treating specific clinical conditions.


Q: Can Atn-50 affect my sleep schedule?

Official safety information lists sleep disturbances and nightmares as reported adverse reactions. If this occurs, it is generally considered an uncommon effect.


Q: Is Atn-50 known to cause long-term side effects?

Regulatory documents cover risks associated with chronic administration. The label describes an adverse reaction profile based on use over time and requires the need for periodic monitoring.


Q: How long does Atn-50 stay in my system?

The elimination half-life of oral Atn-50 is approximately 6 to 7 hours. This value describes the time it takes for half of the drug to be cleared from the body, and this process may be prolonged in patients with impaired kidney function.


Q: Can Atn-50 be used by children?

Official documents often state that there is limited or no established experience with the use of Atn-50 in children. Established experience for its use in children is often limited or not documented in regulatory approvals.


Q: What type of medicine class does Atn-50 belong to?

Atn-50 is officially categorized as a beta-blocker. It belongs to a group of medicines known as beta1 ext-selective beta-adrenergic receptor blocking agents.


Q: Is Atn-50 considered a controlled substance?

Official drug classification systems indicate that Atn-50 is not designated as a controlled substance by regulatory bodies.


Q: Do I need to have my blood tested regularly while taking Atn-50?

Documentation on the drug notes potential changes in laboratory values, such as elevated liver enzymes (transaminases), have been documented as an uncommon adverse reaction. Periodic monitoring is a common practice when using medications for chronic conditions.


Q: Is Atn-50 used to treat anxiety or depression?

The drug is not officially indicated for the treatment of anxiety or depression. Its approved uses, as listed on the regulatory label, are specifically related to cardiovascular conditions like hypertension and angina.


Q: What does the number '50' in Atn-50 refer to?

The number '50' in the name Atn-50 typically refers to the tablet strength of 50 milligrams (mg). This is a common starting dose for the oral therapy of the medication.


Q: Are there any known serious, but rare, side effects of Atn-50?

Yes, official documents list serious, but rare, events that have been documented. These include the precipitation of heart block and bronchospasm (a sudden difficulty breathing) in patients with underlying lung or bronchial disease.


Q: Can I drive or operate machinery after taking Atn-50?

Official documents caution that the drug may cause effects like dizziness or fatigue. These effects can potentially impair a person's ability to drive or safely operate heavy machinery.


Q: Is Atn-50 a drug that is only used short-term?

No, official regulatory indications include the chronic management of long-term conditions such as hypertension and angina. This means its use is often intended to be ongoing rather than short-term.


Q: What are the main differences between Atn-50 and a placebo in clinical trials?

Clinical trials reported that patients receiving Atn-50 showed differences from the placebo group, including measurements related to lowered systolic and diastolic blood pressure. This reduction in blood pressure is a key outcome that supports its use.


Q: Does taking Atn-50 affect my ability to concentrate?

Official safety documents list psychiatric and central nervous system effects, such as confusion or lethargy (a state of weariness). These effects could potentially impact a person's ability to concentrate.


Q: Are there any official documents that clarify common misunderstandings about Atn-50?

Yes, patient-focused resources like the NIH MedlinePlus and the Patient Counseling Information section of official labels provide clear and simplified information designed to help patients understand and use the medication properly.


Q: How is Atn-50 regulated by agencies like the FDA or EMA?

Agencies such as the U.S. FDA and the European Medicines Agency (EMA) are responsible for reviewing and approving the drug. Their role is to define its official indications (approved uses) and establish its complete safety profile based on rigorous testing.


Q: Are there any known risks of taking Atn-50 long-term?

The regulatory label covers risks associated with chronic use. A documented risk involves serious cardiovascular events following the abrupt cessation of treatment, necessitating a required gradual dose reduction (tapering) process.


Q: Is Atn-50 a drug that is used for pain relief?

The approved indications for Atn-50 are related to cardiovascular conditions, such as hypertension and angina. It is not officially indicated for general pain relief.


Q: Does Atn-50 require any special preparation before taking it?

Official administration instructions state that the tablets are intended to be swallowed whole with water. The medication may also be taken with or without food.


How should Atn-50 be stored and disposed of?

How to Store and Dispose of Atn-50

The official labeling specifies strict storage and disposal requirements for Atn-50 (Atenolol) to maintain the medicine's integrity and purity.


Storage Requirements

Condition Regulatory Requirement
Temperature Ceiling Do not store above 25 C (seventy-seven degrees Fahrenheit).
Packaging Store in the original package, and keep the container tightly closed.
Child Safety Must be kept out of the sight and reach of children.

Storage conditions are designed to maintain the product's quality throughout its stated shelf-life. The mandate to keep the container tightly closed serves to protect the tablets from environmental moisture.


Disposal

Disposal of unused or expired Atn-50 must be completed in accordance with local requirements for pharmaceutical waste. Medicine should not be thrown into household waste or flushed down the toilet unless specifically authorized by an official local take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atn-50 found in:

A-Z Index: